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Abstract
Introduction: Varenicline is widely used for smoking cessation. It has shown efficacy over placebo
and bupropion in manufacturer-sponsored trials. Those with mental illness were excluded from these
trials. There are case reports of exacerbation of mental illness and development of psychiatric
symptoms with varenicline use.
Case presentation: A 61-year-old male Caucasian being treated for post-traumatic stress disorder,
depression not otherwise specified and alcohol dependence, was prescribed varenicline while he was
in a post-traumatic stress disorder/alcohol dual diagnosis treatment program. He developed visual
hallucinations, which became worse with titration of the medication. These symptoms resolved upon
discontinuation of varenicline.
Conclusion: Patients with mental illness have a higher incidence of nicotine dependence, and
attempts should be made for smoking cessation. Varenicline has not been widely tested in this
population. There are reports of exacerbation of mental illness, and probable causation of psychiatric
symptoms in the mentally ill. Providers should be aware of this possibility and advise their patients
appropriately.
Introduction
The FDA approved varenicline in 2006 as an aid to
smoking cessation. It provides a unique mechanism
compared to nicotine replacement therapy. It is a partial
agonist selective for the alpha 4 beta 2 nicotinic acetylcho-
line receptor subtype. It provides a low to moderate level
of dopamine stimulation, which is believed to alleviate
craving and nicotine withdrawal symptoms. Additionally,
this medication is an antagonist at nicotine receptors,
which may reduce the reinforcing effects of nicotine and
decrease the risk of relapse [1].
Psychiatric side effects are listed as a rare occurrence in the
product information. Hallucinations, bradyphrenia,
euphoric mood, psychotic disorders and suicidal ideation
are listed as rare treatment emergent events [2]. Case
reports have been published highlighting the potential for
serious psychiatric side effects of this medication (Table 1)
[3-5]. Jorenby et al. [6] reported acute psychosis, and
emotional lability as serious adverse effects that occurred
in a patient during treatment with varenicline, and
continued in the patient following discontinuation of
treatment . The nature of the psychosis is not described. In
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professionals regarding reports of suicidal thoughts, and
aggressive and erratic behavior in patients on varenicline.
In May 2008, the FDA advised that prescribing informa-
tion for varenicline was revised to include information on
serious neuropsychiatric symptoms in the WARNINGS
and PRECAUTIONS sections of the label [7].
Subsequently, a report by Moore et al. [8] for The Institute
for Safe Medication Practices expressed immediate safety
concerns about the use of varenicline in patients in whom
lapses of alertness or motor control could lead to massive
serious injury. They recommended caution with vareni-
cline use, and consideration of alternative methods of
smoking cessation. They also urged the FDA and the
manufacturer to provide appropriate warnings, and to
undertake further investigation. The report states that
between May 2006 and December 2007, 55 cases of
hallucinations were reported. It is not clear whether visual
hallucinations were reported amongst these.
Stapleton et al. [9] conducted a study with 412 participants
at an NHS tobacco dependence clinic in London, UK,
where none of the abovementioned exclusion criteria were
used. Twenty seven percent of the patients reported they
were being treated for mental illnesses including depres-
sion, bipolar disorder, psychosis, and eating disorders. The
investigators reported no evidence of exacerbation of
mental illness symptoms by varenicline at the manufac-
turer recommended schedule, nor any evidence that
adverse symptoms were experienced more in those with
mental illness. Interestingly though, one participant had a
severe psychological reaction, likened to a “bad LSD trip”,
including anxiety, paranoia, confusion and impaired
motor control, that was not explained further. Sustained
release of dopamine is postulated to be a contributing
factor to the development of symptoms of psychosis.
Case presentation
A 61-year-old Caucasian male army veteran had been
treated as an outpatient for the last 2 years for post-
traumatic stress disorder (PTSD), alcohol dependence, and
depression not otherwise specified (NOS). Before this, he
had been symptomatic, but did not present for treatment.
He was admitted to a residential PTSD/alcohol dual
diagnosis treatment program. His medications upon
admission were fluoxetine 20 mg every morning for
depression, nortriptyline 25 mg at bedtime for sleep and
depression, quetiapine 50 mg at bedtime and every 6
hours as needed for anxiety, prazosin 1 mg at bedtime for
nightmares, pramipexole 0.5 mg at bedtime for restless
legs syndrome, terazosin 5 mg at bedtime for benign
prostatic hypertrophy, atenolol 50 mg daily, and spirono-
lactone 50 mg daily, for hypertension. He had been on all
these medications for at least 6 months, with no reported
adverse effects. He had smoked 2 packs of cigarettes per
day for the past year, and had previously smoked four
packs per day, for about 30 years. The patient’s diagnosis
of restless legs syndrome was made before any treatment
he received for mental illness, and was not thought to be a
medication adverse effect. His laboratory studies were
negative and he did not have anemia (his hemoglobin
level was 13.5 just before his enrolment in the treatment
program).
The patient ceased using alcohol 1 month before entering
the treatment program. He denied using any alcohol
throughout the duration of the residential program, and
no such evidence was found to the contrary by his health
care providers. Three weeks before completion of the
program, he was prescribed varenicline for smoking
cessation, at the manufacturer recommended titration.
This was prescribed by a provider at the treatment
program. Subsequently, the patient reduced his smoking
to two cigarettes per day.
Upon starting varenicline, he reported experiencing visual
hallucinations. This was unusual to him as he reports that
he had never experienced visual or other hallucinations in
the past. Onincreasing the medication to 1 mg twice daily,
his visual hallucinations became more frequent and more
vivid. He reported seeing ropes dangling in the air and
birds flying around the room. Nineteen days after the
commencement of varenicline, he was discharged to
home. Initially, he had not reported his symptoms to his
providers or family, fearing that they would think he was
“crazy”. On the trip home, his wife noticed his behavior
had changed. She reported that on the drive home he was
leaning over as though avoiding something and it
appeared to his wife that he was “seeing things”. His
wife reported that he was also reaching out in the air as if
to grasp something.
Upon arrival at home, he read through the drug
information provided by the pharmacy and noted that
hallucinations could be a side effect. He immediately
discontinued varenicline, without consulting his physi-
cian, and the hallucinations reduced, and resolved over a
Table 1. Case reports
Author Patient
gender
and age
Pre-existing
diagnosis
Symptoms with
varenicline use
Freedman [3] Female, 42 Schizophrenia 5-day psychotic
episode
Kohen and
Kremen [4]
Male, 63 Bipolar disorder Manic episode
Morstad et al.
[5]
Female, 41 Bipolar Disorder
Type II and
polysubstance abuse
Hypomania with
agitation
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regular mental health physician provider at his next office
visit. According to DSM-IV-TR criteria, a diagnosis of
Psychotic Disorder Not Otherwise Specified would be
appropriate [10]. No further investigations were per-
formed at this time as he was asymptomatic.
On applying the Naranjo causality scale, a score of 6 was
obtained, indicating a probable adverse drug reaction to
varenicline [11]. It is important to note that we took into
consideration that this patient was on pramipexole, a
dopamine agonist, which could have contributed to his
symptoms. However, the patient had been using this
medication for many months and had not reported signs
or symptoms of psychosis.
Discussion
Nicotine is believed to act through the neurobiological
reward pathways in the brain, most notably involving
dopamine, but also other neurotransmitters. Smoking
tobacco stimulates a rapid rise in dopamine in the nucleus
accumbens, which is believed to contribute to the addictive
properties of nicotine [1]. Tolerance may develop in heavy
smokers, resulting in increased use, and dependence.
Attempts at smoking cessation may be difficult due to
nicotine withdrawal symptoms. Criteria for nicotine
withdrawal include dysphoric mood, insomnia, irritabil-
ity, frustration or anger, anxiety, difficulty concentrating,
restlessness, decreased heart rate, and increased appetite or
weight gain [10]. Nicotine withdrawal symptoms are
expected to be of short duration, and to improve with
time. Visual hallucinations have not, to our knowledge,
been described in the literature as a symptom of nicotine
withdrawal.
Nicotine receptor partial agonists, such as varenicline,
may help smoking cessation by selectively activating the
alpha 4 beta 2 neuronal nicotinic acetylcholine recep-
tors. These receptors modulate the effects of the
mesolimbic dopamine pathways, which mimic nicotine,
thus helping counteract withdrawal symptoms. These
medications may also block the dopamine releasing
effect of nicotine, thus reducing pleasure from smoking.
Varenicline was developed from cytisine, a naturally
occurring alkaloid compound, shown to be an effective
partial agonist for the alpha 4 beta 2 receptor. Cytisine
has been used in central and eastern Europe for smoking
cessation for over 40 years [12]. A literature review and
meta-analysis of research conducted on cytisine sug-
gested that it is effective for smoking cessation. One of
the published studies reviewed included patients with
mental illness. They reported adverse effects, and toxic
effects of cytisine, which did not include symptoms of
psychosis [13].
Amongst the exclusion criteria for the phase three
varenicline trials were major depressive disorder within
the previous 12 months requiring treatment, history of or
current panic disorder, psychosis, bipolar disorder or
eating disorder; alcohol or drug abuse/dependency within
the previous 12 months, as well as psychogenic medica-
tion use [14,15]. Psychiatric side effects are listed as a rare
occurrence in the product information [2]. Hallucinations,
bradyphrenia, euphoric mood, psychotic disorders and
suicidal ideation are listed as rare treatment emergent
events [2]. Further details of these adverse effects are not
available in the published medical literature.
There are also reports of individuals with psychiatric
disorders using varenicline without subsequent adverse
effects. Fatemi reported a case of a patient with schizo-
phrenia who reduced his tobacco use to five cigarettes per
day with 24 months of varenicline utilization, who did not
experience any exacerbation of his psychiatric symptoms
[16]. Evins and Goff report a series of 19 psychiatrically
stable patients with schizophrenia who did not experience
a psychiatric re-hospitalization or exacerbation of their
symptoms with 24 weeks of varenicline use [17]. Exact
treatment recommendations cannot be drawn from these
case reports as to the utility of varenicline in patients with
psychiatric illnesses.
Conclusion
We report a patient with visual hallucinations that
developed with varenicline use. The patient had pre-
existing mental illness. Many patients with mental illness
are concurrent smokers and the use of this product has
become very common in this population. At the writing of
this paper, three cases have been published showing
exacerbation of mental illness from varenicline (Table 1).
The FDA and the Institute for Safe Medication Practices
have advised providers of suicidal thoughts, depressed
mood, aggressive and erratic behavior, and other neurop-
sychiatric symptoms with varenicline use. Patients with
mental illness have a higher incidence of nicotine
dependence, and attempts should be made at smoking
cessation. Treatment should include behavioral and
pharmacological strategies as necessary. Although patients
withpsychiatric illnesshave used varenicline with reported
efficacy and tolerability, caution needs to be used in this
population. This case highlights the need for providers to
be aware of potential psychiatric symptoms with vareni-
cline use. Providers should prescribe with caution and
provide relevant education and monitoring to patients
with underlying mental illness.
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